Muthu V. Kumaran

Professor

UAMS

Also affiliated: Temple University (2020–2022)

Faculty Researcher

2 h-index 9 pubs 8 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Muthu V. Kumaran's research focuses on dermatology and immunology, with a particular interest in conditions such as vitiligo and drug reactions. He has investigated the efficacy of oral cyclosporine in stabilizing active vitiligo and explored the role of dendritic cell subsets in inflammatory cytokine production in progressive vitiligo. Kumaran has also studied predictors of severe drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, and evaluated factors influencing their outcomes. His work extends to the impact of COVID-19 on dermatological conditions, including urticaria exacerbations following vaccination and the use of teledermatology during the pandemic. Collaborations include work with Mamatha Gaddam, Ankur Varma, César Sánchez, and Nishanth Thalambedu, all at the University of Arkansas for Medical Sciences.

Metrics

h-index: 2
Publications: 9
Citations: 8

Selected Publications

In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)

DOI OpenAlex
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas. (2026)

DOI OpenAlex
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL (2026)

Blood 3 citations DOI OpenAlex
Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world (2025)

Blood 2 citations DOI OpenAlex
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia (2025)

Blood Advances 3 citations DOI OpenAlex
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (2025)

Bone Marrow Transplantation 1 citation DOI OpenAlex
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)

Diagnostics 6 citations DOI OpenAlex
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement (2025)

Blood Advances 5 citations DOI OpenAlex
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy (2025)

Blood Advances 14 citations DOI OpenAlex
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)

Cancers 5 citations DOI OpenAlex
Impact of Response to Bridging Therapy on Outcomes of CAR-T Therapy in Relapsed/Refractory DLBCL: A Single Center Retrospective Analysis (2024)

DOI OpenAlex
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above (2024)

Blood 3 citations DOI OpenAlex
NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival (2024)

Blood 3 citations DOI OpenAlex